Showing results (121-130 of 141) with videos related to
Sort By:
Pageof 15
Thyroid : Official Journal of the American Thyroid Association|July 24, 2015
Reassessing the NTCTCS Staging Systems for Differentiated Thyroid Cancer, Including Age at DiagnosisDonald S A McLeod, Jacqueline Jonklaas, James D Brierley, et al.Thyroid : Official Journal of the American Thyroid Association|January 25, 2017
American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear FeaturesBryan R Haugen, Anna M Sawka, Erik K Alexander, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2011
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancerRazelle Kurzrock, Steven I Sherman, Douglas W Ball, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2013
Cabozantinib in progressive medullary thyroid cancerRossella Elisei, Martin J Schlumberger, Stefan P Müller, et al.The Journal of Clinical Endocrinology and Metabolism|September 24, 2016
Bone Metastases and Skeletal-Related Events in Medullary Thyroid CarcinomaJian Yu Xu, William A Murphy, Denái R Milton, et al.Biorxiv : the Preprint Server for Biology|August 12, 2025
Activating <i>RET</i> Mutations Promotes Osteoblastic Bone Metastases in Medullary Thyroid CancerRozita Bagheri-Yarmand, Gabriel M Pagnotti, Joseph L Kidd, et al.Cancer|April 28, 2015
A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessmentMaria E Cabanillas, Martin Schlumberger, Barbara Jarzab, et al.Annals of Surgical Oncology|February 11, 2018
Recontacting Patients with Updated Genetic Testing Recommendations for Medullary Thyroid Carcinoma and Pheochromocytoma or ParagangliomaMinerva A Romero Arenas, Thereasa A Rich, Samuel M Hyde, et al.The New England Journal of Medicine|February 12, 2015
Lenvatinib versus placebo in radioiodine-refractory thyroid cancerMartin Schlumberger, Makoto Tahara, Lori J Wirth, et al.The Journal of Clinical Endocrinology and Metabolism|January 6, 2006
A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawalPamela R Schroeder, Bryan R Haugen, Furio Pacini, et al.Pageof 15